Nature Reviews Drug Discovery

Nature Reviews Drug Discovery (nature-reviews-drug-discovery)

Journal positioning

Nature Reviews Drug Discovery is a Springer Nature title and the field-defining review journal for drug discovery and development. Its defining character is authoritative, commissioned synthesis: it publishes no primary research, and the great majority of content is solicited by the editors from leaders in pharmacology, medicinal chemistry, translational medicine, and pharma R&D strategy. The journal rewards reviews and analyses that frame where a therapeutic area, target class, or development paradigm stands and where it is heading — integrating mechanism, clinical evidence, pipeline landscape, and commercial and regulatory context — rather than narrow methodological updates. Readership spans academic pharmacologists, biotech and pharma scientists, clinicians, and investors. This skill is a fit / venue-selection / re-framing tool. It does not replace the journal's current official submission guidelines. Because most articles are commissioned, an unsolicited submission almost always begins with a pre-submission proposal. Before submitting, re-check the live author instructions on the Nature Reviews Drug Discovery site.

When to trigger

• The author is preparing a commissioned or proposed review on a drug target, modality, therapeutic area, or aspect of pharma R&D and names this journal as the venue.
• A manuscript synthesizes the state of drug discovery or development for a field — integrating biology, clinical data, and pipeline landscape — and the author is choosing between this journal and Nature Medicine, Nature Reviews Methods Primers, or Cell Reports Medicine.
• The author has a primary-research drug-discovery study and needs to be redirected, because this journal publishes no original data.
• The author needs the journal's commissioning norms, scope boundaries, and desk-reject criteria before drafting a proposal.

Scope & topic fit

• Target and pathway reviews: the biology, druggability, and clinical translation of a target class — kinases, GPCRs, ion channels, epigenetic regulators, protein-protein interactions — across discovery and development.
• Modality and platform reviews: small molecules, biologics, antibody-drug conjugates, cell and gene therapies, RNA therapeutics, PROTACs and targeted degraders, covering chemistry, delivery, and clinical maturity.
• Therapeutic-area landscapes: oncology, immunology, neurology, metabolic and infectious disease — synthesizing mechanism, the development pipeline, and unmet need.
• Drug discovery and development paradigms: AI/ML in discovery, translational biomarkers, clinical trial design innovation, drug repurposing, and the science of attrition and productivity.
• Regulatory, R&D-strategy, and pipeline analyses: approval trends, the economics of development, and data-driven assessments of where investment and innovation are concentrated.
• Mechanism-of-action and pharmacology reviews where the clinical-development implications are central, not incidental.

Method & evidence bar

• The central thesis must be identifiable in one or two sentences: a clear argument about the state and trajectory of a field, not an undifferentiated catalog of papers.
• Claims must be evidence-based and current: clinical-stage assertions should reflect the latest trial readouts and approval status, with pipeline data sourced and dated.
• Mechanistic claims must rest on the strongest available evidence; the review should weigh conflicting findings rather than report them uncritically.
• Figures and tables are a core deliverable: mechanism schematics, target/pipeline landscape tables, and trial-summary tables are expected to add synthesis, not merely illustrate.
• Quantitative analyses (approval rates, attrition, pipeline counts) must state data sources, cut-off dates, and methods so the numbers are reproducible.
• Where the review covers clinical evidence, it should reflect the relevant reporting and evidence standards (e.g., quality of underlying CONSORT-compliant trials, registration status) when appraising trial data.

Structure & house style

• Articles are commissioned; unsolicited work normally enters through a pre-submission proposal (synopsis, outline, author expertise) that the editors evaluate before inviting a full manuscript.
• Nature Reviews enforces defined length, display-item, and reference limits by article type (Review, Perspective, Analysis); re-check current limits on the live site.
• The writing is authoritative and accessible to a cross-disciplinary readership; jargon is explained, and the narrative builds an argument rather than surveying exhaustively.
• Display items carry much of the synthesis: schematic figures redrawn by the in-house art team, plus structured tables of targets, agents, and trials; authors supply clear source sketches and complete data.
• Boxes are used for self-contained background, definitions, or methodological asides so the main text keeps its narrative line.
• A structured summary and key-points list orient the reader; abstracts and headings follow the Nature Reviews template.